SOHO 2020 – VJRegenMed

Immunotherapy for T-cell malignancies

admin_vjr_user — Tue, 03 Nov 2020 17:39:54 +0000

John DiPersio, MD, PhD, Washington University, St. Louis, MO, discusses recent advances in the use of cellular therapies for T-cell malignancies including T-cell acute lymphoblastic leukemia and T-cell non-Hodgkin lymphoma, including using CRISPR gene editing to eliminate the target on the effector T-cell to prevent fratricide, as well as using off-the-shelf allogeneic T-cells to prevent contamination of tumor cells. This interview was recorded via an online conference call with The Video Journal of Regenerative Medicine (VJRegenMed).

Next questions in CAR-based therapies

admin_vjr_user — Tue, 03 Nov 2020 17:39:54 +0000

John DiPersio, MD, PhD, of Washington University, St. Louis, MO, outlines the next questions in CAR-based therapies and new approaches to improving the efficacy of CAR T-cells including generating CAR T-cells that can target multiple antigens, as well as improving the persistence of CAR T-cells in vivo. This interview was recorded via an online conference call with The Video Journal of Regenerative Medicine (VJRegenMed).

Innovative CAR designs

admin_vjr_user — Thu, 08 Oct 2020 14:08:16 +0000

Renier J. Brentjens, MD, PhD, Memorial Sloan-Kettering Cancer Center, New York, NY, discusses novel CAR designs aimed to improve the efficacy of CAR T-cell recipients, including the development of armored CAR T-cells able to further penetrate malignancies. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc)

Impact of COVID-19 on CAR T-cell therapies

admin_vjr_user — Thu, 08 Oct 2020 14:08:16 +0000

David L. Porter, MD, University of Pennsylvania, Abramson Cancer Center, Philadelphia, PA, explores the impact of the COVID-19 pandemic on the treatment and management of patients with hematological malignancies treated with CAR T-cell therapies, which are widely recognized as high-risk interventions. This interview was recorded via an online conference call with The Video Journal of Regenerative Medicine (VJRegenMed).

Challenges in CAR T-cell therapy

admin_vjr_user — Thu, 08 Oct 2020 14:08:16 +0000

Renier J. Brentjens, MD, PhD, Memorial Sloan-Kettering Cancer Center, New York, NY, outlines the major challenges in CAR T-cell therapies including remission and relapse rate, cost, as well as targeting associated toxicities. This interview was recorded via an online conference call with The Video Journal of Regenerative Medicine (VJRegenMed).

Point-of-care CAR T-cells

admin_vjr_user — Thu, 08 Oct 2020 14:08:16 +0000

Marcos de Lima, MD, UH Cleveland Medical Center, Cleveland, OH, discusses the significance of point-of-care CAR T-cell therapies. This interview was recorded via an online conference call with The Video Journal of Regenerative Medicine (VJRegenMed).

CAR-T therapy for aggressive B-cell lymphomas

admin_vjr_user — Thu, 08 Oct 2020 14:08:15 +0000

Peter A. Riedell, MD, University of Chicago Medicine, Chicago, IL, discusses the use of CAR T-cell therapies for patients with aggressive B-cell lymphomas, including tisagenlecleucel and axicabtagene ciloleucel, both approved by the FDA in the third-line setting for patients with aggressive B-cell lymphomas. This interview was recorded via an online conference call with The Video Journal of Regenerative Medicine (VJRegenMed).

Anti-CD19 CAR T-cells for adults

admin_vjr_user — Thu, 08 Oct 2020 14:08:15 +0000

David L. Porter, MD, University of Pennsylvania, Abramson Cancer Center, Philadelphia, PA, outlines the use of CD-19 CAR T-cells for adults with lymphoma and leukemia, specifically discussing the sustained remissions seen in patients treated with tisagenlecleucel and axicabtagene ciloleucel. This interview was recorded via an online conference call with The Video Journal of Regenerative Medicine (VJRegenMed).

State-of-the-art in CAR-T

admin_vjr_user — Thu, 08 Oct 2020 14:08:15 +0000

Peter A. Riedell, MD, University of Chicago Medicine, Chicago, IL, provides an outlook in the current CAR-T climate and where things are moving in the future, including a better understanding of response, T-cell exhaustion and CD19 antigen loss. This interview was recorded via an online conference call with The Video Journal of Regenerative Medicine (VJRegenMed).

Long-term outcomes of anti-CD19 CAR-T in R/R CLL

admin_vjr_user — Thu, 08 Oct 2020 14:08:15 +0000

David L. Porter, MD, University of Pennsylvania, Abramson Cancer Center, Philadelphia, PA, explores the long-term outcomes from a randomized dose optimization study of CAR-modified T-cells in relapsed/refractory (R/R) chronic lymphoyctic leukemia (CLL). This interview was recorded via an online conference call with The Video Journal of Regenerative Medicine (VJRegenMed).